Argitalpenak (78) SARA LÓPEZ TARRUELLA COBO argitalpenak

2024

  1. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study

    Breast Cancer Research and Treatment, Vol. 203, Núm. 1, pp. 163-172

  2. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment

2023

  1. Assessment of a Genomic Assay in Patients with ERBB2 -Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy with or Without Pertuzumab

    JAMA Oncology, Vol. 9, Núm. 6, pp. 841-846

  2. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Annals of Oncology, Vol. 34, Núm. 9, pp. 783-795

  3. Impact of the COVID-19 Lockdown on Physical Activity Levels and Health Parameters in Young Adults with Cancer

    Current Oncology, Vol. 30, Núm. 6, pp. 5395-5408

  4. Laser transfer for circulating tumor cell isolation in liquid biopsy

    International Journal of Bioprinting, Vol. 9, Núm. 4, pp. 1-14

  5. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

    Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159

2022

  1. A Standardized Liquid Biopsy Preanalytical Protocol for Downstream Circulating-Free DNA Applications

    Journal of Visualized Experiments, Vol. 2022, Núm. 187

  2. A prospective observational study for a Federated Artificial Intelligence solution for moniToring mental Health status after cancer treatment (FAITH): study protocol

    BMC Psychiatry, Vol. 22, Núm. 1

  3. HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping

    Cancers, Vol. 14, Núm. 3

  4. How we treat HR-positive, HER2-negative early breast cancer

    Future oncology (London, England), Vol. 18, Núm. 8, pp. 1003-1022

  5. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    The Lancet. Oncology, Vol. 23, Núm. 1, pp. 149-160

  6. The importance of physical exercise in cardiovascular fitness in breast cancer survivors. A cross-sectional study: women in Motion 2.0

    Supportive Care in Cancer, Vol. 30, Núm. 8, pp. 6745-6754

2021

  1. Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts

    Scientific Reports, Vol. 11, Núm. 1

  2. Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice

    Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681

  3. Dpyd exome, mrna expression and uracil levels in early severe toxicity to fluoropyrimidines: An extreme phenotype approach

    Journal of Personalized Medicine, Vol. 11, Núm. 8

  4. Technical challenges for CTC implementation in breast cancer

    Cancers, Vol. 13, Núm. 18

2020

  1. Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1-refractory tumors

    Science Translational Medicine, Vol. 12, Núm. 565

  2. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations

    Drugs, Vol. 80, Núm. 2, pp. 131-146

  3. Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

    Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 717-724